Answers are grounded in this paper and cite their sources.
This review summarizes current European guidelines on antiplatelet therapy, highlighting the need for personalized DAPT duration based on individualized bleeding and ischemic risk assessments.
In the presented review, some of the main points of the new European recommendations on the use of double antiplatelet therapy (DAT) and triple antithrombotic therapy in patients with coronary heart disease (CHD) with different approaches to its treatment (conservative, invasive and surgical) are outlined. The positions of acetylsalicylic acid (ASA) are designated as the primary basis of a prophylactic antiplatelet strategy. Attention is paid to a new risk stratification for the calculation of the duration of DAT, recommendations for the proper choice of receptor inhibitors for adenosine diphosphate type P2Y12, for switching between oral inhibitors of P2Y12 and for the duration of DAT in different forms of CHD. The review discusses adherence to therapy with ASA and DAT.
No takes yet. Share an insight, caveat, or question.
Бубнова et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: